Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen

被引：0
|
作者：
Lu, D.
Krop, I.
Modi, S.
Elias, A.
LoRusso, P.
Huang, J.
Lu, M.
Girish, S.
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Colorado, Sch Med, Aurora, CO USA
[5] Wayne State Univ, Detroit, MI USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-22
引用
收藏
页数：1
相关论文
共 50 条
  • [31] MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
    Ellis, P. A.
    Barrios, C. H.
    Im, Y.
    Patre, M.
    Branle, F.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] TARGETING HER2 WITH TRASTUZUMAB-DM1 (T-DM1) IN HER2-OVEREXPRESSING BLADDER CANCER
    Hayashi, Tetsutaro
    Jaeger, Wolfgang
    Moskalev, Igor
    Awrey, Shannon
    Li, Na
    Fazli, Ladan
    Yasui, Wataru
    Matsubara, Akio
    Black, Peter
    JOURNAL OF UROLOGY, 2014, 191 (04): : E301 - E301
  • [33] Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC)
    Wang, Bei
    Jin, Jin
    Wada, Russell
    Fang, Liang
    Lu, Dan
    Guardino, Ellie
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Pegram, Mark D.
    Blackwell, Kimberly
    Miles, David
    Bianchi, Giulia Valeria
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [35] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Blackwell, Kimberly L.
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark D.
    Do-Youn Oh
    Dieras, Veronique
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael W.
    Guardino, Ellie
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
  • [38] Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Li, Chunze
    Wang, Bei
    Lu, Dan
    Jin, Y.
    Gao, Yuying
    Matsunaga, Kiyoshi
    Igawa, Yuriko
    Nijem, Ihsan
    Lu, Michael
    Strasak, Alexander
    Chernyukhin, Nataliya
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 547 - 558
  • [39] Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).
    Wuerstlein, Rachel
    Ellis, Paul
    Montemurro, Filippo
    Anton Torres, Antonio
    Delaloge, Suzette
    Zhang, Qingyuan
    Wang, Xiaojia
    Wang, Shusen
    Shao Zhimin
    Li, Huiping
    Rachman, Andhika
    Vongsaisuwon, Mawin
    Liu, Haiying
    Fear, Simon
    Pena-Murillo, Claudia
    Barrios, Carlos H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Kanemaki, Yoshihide
    Boku, Narikazu
    Tsugawa, Koichiro
    ONCOLOGY, 2019, 96 (06) : 309 - 317
12345